个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Nan Chuanchuan[1,2,4] * ; Zhang Xiaowu[3] * ; Huang Wei[2] * ; Zhu Biao[5] * ; Zhao Jianghong[6] * ; Lu Song[7] * ; Xian Lewu[8] * ; Liu Kaizhong[9] ; Ma Gang[10] ; Yang Wei[1] ; Huang Mingguang[11] ; Zhou Dongmin[12] ; Zhang Ming[13] ; Duan Yan[11] ; Wu Guixin[14] ; Jiang Zhengying[14] ; Zhang Li[15] ; He Xinrong[10] ; Chen Yuhong[16] ; Xing Xuezhong[17] ; Wang Changsong[1,2,*1] ; Wang Donghao[3] ; Yu Kaijiang[1] ;
机构： [1]Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China [2]Department of Critical Care Medicine, Harbin Medical University Cancer Hospital, Harbin 150001, China [3]Department of Critical Care Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China [4]Department of Critical Care Medicine, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518000, China [5]Department of Critical Care Medicine, Shanghai Cancer Center of Fudan University, Shanghai 200032, China [6]Department of Critical Care Medicine, Hunan Cancer Hospital, Changsha 410013, China [7]Department of Critical Care Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China [8]Department of Critical Care Medicine, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510000, China [9]Department of Critical Care Medicine, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou 310022, China [10]Department of Critical Care Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510000, China [11]Department of Critical Care Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, China [12]Department of Critical Care Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, China [13]Department of Critical Care Medicine, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou 310022, China [14]Department of Critical Care Medicine, Chongqing University Cancer Hospital, Chongqing 404100, China ◦ [15]Department of Critical Care Medicine, Hubei Cancer Hospital, Wuhan 430079, China [16]Department of Critical Care Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China [17]Department of Critical Care Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100000, China
出处：
DOI： 10.1016/j.phrs.2023.106991
ISSN：

关键词： Carrimycin CD8+ T cells HLA-DR Immune Sepsis Tumor

摘要：
Carrimycin is a potential immune-regulating agent for sepsis in patients with tumors. In this study, we investigated its effects on inflammation and immune function in tumor patients with sepsis. In total, 120 participants were randomized to receive either carrimycin treatment (400 mg/day) (n = 62) or placebo (n = 58) for 7 days. The primary outcomes were immune-related indicators. Subsequently, patients were stratified into two subgroups (CD4 < 38.25% and CD8 < 25.195%). Ninety-nine participants were analyzed: 47 and 52 in the carrimycin and placebo groups, respectively. HLA-DR levels were rapidly increased in the carrimycin group; however, the placebo group initially experienced a decline in HLA-DR level at 1 day after administration. In the subgroup with CD4 < 38.25%, the carrimycin group exhibited significantly higher HLA-DR levels than the placebo group (2.270, P = 0.023) 1 day after administration and the degree of increase in HLA-DR in the carrimycin group was higher than that in the placebo group (2.057, P = 0.040). In the CD8 < 25.195% subgroup, the carrimycin group demonstrated significantly higher levels of CD8+ T cells than the placebo group at 3 (2.300,P = 0.027) and 5 (2.106, P = 0.035) days after administration. Carrimycin intervention led to significant reductions in the SOFA, APACHE II, PCT, and CRP levels. No adverse events were observed. In tumor patients with sepsis, particularly in those experiencing immunological suppression, carrimycin effectively regulates immune responses by increasing HLA-DR and CD8+ T cell levels and plays an anti-infective role, reducing disease severity. (Chictr.org.cn, ID Number: ChiCTR2000032339).Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

基金：
This trial was funded by Shanghai Tonglian Pharmaceutical Co. Ltd. The funders were not involved in the trial design, data collection and interpretation, or manuscript preparation.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 1 区 药学
最新[2025]版：
大类 | 2 区 医学
小类 | 1 区 药学
JCR分区：
出版当年[2023]版：
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版：
Q1 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China [2]Department of Critical Care Medicine, Harbin Medical University Cancer Hospital, Harbin 150001, China [4]Department of Critical Care Medicine, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518000, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China [2]Department of Critical Care Medicine, Harbin Medical University Cancer Hospital, Harbin 150001, China [*1]Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China. Department of Critical Care Medicine, Harbin Medical University Cancer Hospital, Harbin 150001, China
推荐引用方式(GB/T 7714)：
Nan Chuanchuan,Zhang Xiaowu,Huang Wei,et al.Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial[J].PHARMACOLOGICAL RESEARCH.2023,198:doi:10.1016/j.phrs.2023.106991.
APA：
Nan Chuanchuan,Zhang Xiaowu,Huang Wei,Zhu Biao,Zhao Jianghong...&Yu Kaijiang.(2023).Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial.PHARMACOLOGICAL RESEARCH,198,
MLA：
Nan Chuanchuan,et al."Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial".PHARMACOLOGICAL RESEARCH 198.(2023)

相关文献

[1]HLA-DR抗原在斑秃皮损中的表达 [2]Synergistic upregulation of PD&#x2011;L1 in tumor cells and CD39 in tumor&#x2011;infiltrating CD8+ T cells leads to poor prognosis in patients with hepatocellular carcinoma [3]重症脓毒症患者外周血单核细胞mCD14和HLA-DR的表达及临床意义 [4]hB7-1基因转染对人胃癌OCUM-2MD3细胞生长特性及MHCⅠb、HLA-DR抗原表达的影响 [5]PTGR1-mediated immune evasion mechanisms in late-stage triple-negative breast cancer: mechanisms of M2 macrophage infiltration and CD8+ T cell suppression [6]早期强化胰岛素治疗对重症脓毒症患者单核细胞mCD14、HLA-DR表达的影响 [7]Epigenetic modulation combined with PD-1/PD-L1 blockade enhance immunotherapy based on MAGE-A11 antigen specific CD8(+)T cells [8]CD39-Expressing CD8+ T Cells as a New Molecular Marker for Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma [9]红斑狼疮皮损中CD4+和CD8+T细胞的表达 [10]肺癌细胞外泌体mir-24-3p调控cd8+t细胞抗肿瘤的功能及机制研究

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号